Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
ViroGates A/S is a Danish firm specializing in the creation and commercialization of prognostic diagnostic solutions for the medical field. Its flagship product, suPARnostic, is a blood test designed to quantify the soluble urokinase plasminogen activator receptor (suPAR) protein within a patient's circulatory system. This innovative tool empowers hospital emergency rooms to refine their clinical assessments regarding the admission or release of patients with acute medical conditions, thereby contributing to lower healthcare expenditures. Beyond this, ViroGates also supplies several other suPARnostic variations: suPARnostic TurbiLatex, a specialized latex particle-enhanced turbidimetric immunoassay for precise suPAR quantification in specific human plasma samples (K2-EDTA or lithium heparin); the suPARnostic Quick Triage kit, optimized for rapid early warning and patient categorization at the point of care; and suPARnostic ELISA, which delivers comprehensive quantitative readings. The prognostic capabilities of suPAR extend across a broad spectrum of medical conditions, encompassing cardiovascular, renal, oncological, diabetic, hepatic, infectious, respiratory, and rheumatic diseases. Established in 2000, the company maintains its headquarters in Birkerød, Denmark.
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. In particular, the stock is underpriced on P/E.